Can Scleroderma Cause a False-Positive QuantiFERON-TB Gold Test?
No, scleroderma (systemic sclerosis) does not directly cause false-positive QuantiFERON-TB Gold results through disease-specific mechanisms. However, the clinical context requires careful interpretation because both conditions can coexist, and immunosuppressive therapy used in scleroderma management may affect test performance.
Understanding QuantiFERON-TB Gold Specificity
The QuantiFERON-TB Gold assay measures interferon-gamma release in response to specific M. tuberculosis antigens (ESAT-6 and CFP-10). These proteins are absent from BCG vaccine strains and most nontuberculous mycobacteria, which is why the test has superior specificity compared to tuberculin skin testing 1.
Known Causes of False-Positive Results
False-positive QuantiFERON results occur due to:
- Cross-reactivity with specific mycobacteria: M. kansasii, M. szulgai, and M. marinum contain ESAT-6 and CFP-10 1
- High baseline interferon-gamma levels (elevated Nil values >0.7 IU/mL) 1
- Technical/laboratory issues in low-prevalence populations 2
Scleroderma-Specific Considerations
Type I Interferon Activation in Scleroderma
While scleroderma is characterized by type I interferon pathway activation 3, 4, this involves a different interferon system than what QuantiFERON measures. QuantiFERON detects interferon-gamma (type II interferon), not type I interferons. The elevated type I interferon signature in scleroderma patients 3, 4 does not mechanistically cause false-positive QuantiFERON results.
Immunosuppression Effects
Critical caveat: Patients with scleroderma often receive immunosuppressive therapy (mycophenolate, cyclophosphamide, rituximab, tocilizumab) 5. These medications are listed as risk factors for TB progression and can reduce test sensitivity, potentially causing false-negative results rather than false-positives 6, 1.
Clinical Interpretation Algorithm
When encountering a positive QuantiFERON in a scleroderma patient:
Assess TB risk factors independently:
- Geographic origin from TB-endemic areas
- Known TB exposure history
- Occupational risk
- Immunosuppressive medication use 1
Evaluate for active TB disease:
- Chest radiograph for infiltrates or fibrotic changes
- Symptoms: fever, night sweats, weight loss, cough
- Sputum cultures if clinically indicated 1
Review QuantiFERON technical parameters:
Consider repeat testing if initial result is borderline or discordant with clinical picture 1
Evidence from Granulomatous Diseases
Data from sarcoidosis (another granulomatous disease with immune dysregulation) shows that positive QuantiFERON results in these patients likely represent true latent TB infection rather than disease-related false-positives 7. The frequency of positive results in sarcoidosis patients (24.3%) was similar to the general population, and disease activity did not influence results 7.
Key Pitfalls to Avoid
- Do not assume a positive QuantiFERON is false simply because the patient has scleroderma
- Do not ignore true TB risk factors in favor of attributing results to autoimmune disease
- Do not rely on a single negative test in immunosuppressed patients—sensitivity is reduced 6
- Be aware that serial testing in low-risk populations accumulates false-positives over time 2, but this applies to screening programs, not individual diagnostic scenarios
Bottom Line
Interpret the positive QuantiFERON result based on TB risk factors, clinical context, and medication history—not on the presence of scleroderma itself. The autoimmune disease does not create false-positive results through cross-reactivity or interferon dysregulation. If the patient has genuine TB exposure risk or is from an endemic area, treat the result as indicating latent TB infection and proceed with appropriate evaluation for active disease before considering treatment 6, 1.